Dyadic

Historical price data

Dyadic is an industrial biotechnology company with a mission to expand access to essential proteins by making biomanufacturing faster, more affordable, and scalable. Its core achievement is the development of the C1 and Dapibus™ filamentous fungal platforms, proven at commercial scales over 100,000L and validated in a Phase I clinical trial. The company's strategy is to partner across industries, offering flexible engagement models—from selling recombinant proteins to licensing its platforms—to drive adoption and revenue.

Proprietary filamentous fungal expression systems (C1 and Dapibus™) based on Thermothelomyces heterothallica, engineered for high-yield, scalable, and cost-effective production of complex recombinant proteins.

Dyadic competes with traditional expression systems (CHO, E. coli, yeast) and other proprietary microbial platforms. Its differentiation lies in offering eukaryotic protein processing capability at prokaryotic-like economics and scale, but it must overcome significant industry inertia to win major partnerships.